Evidence map›Paper›PMID 34639135›Full record

ReviewInternational journal of molecular sciences2021

Exosomes in Alzheimer's Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics.

Hagar M Soliman, Ghada A Ghonaim, Shaza M Gharib, Hitesh Chopra, Aya K Farag, Mohamed H Hassanin, Abdalrazeq Nagah, Mahmoud Emad-Eldin, Nevertary E Hashem, Galal Yahya and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Hagar M SolimanDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0003-0522-5690
Ghada A GhonaimDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0002-5217-6855
Shaza M GharibDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Hitesh ChopraChitkara College of Pharmacy, Chitkara University, Punjab 140401, India.ORCID 0000-0001-8867-7603
Aya K FaragDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Mohamed H HassaninDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Abdalrazeq NagahDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Mahmoud Emad-EldinDepartment of Clinical, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0001-7451-5400
Nevertary E HashemDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Galal YahyaDepartment of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0002-9466-7863
Sherif E EmamDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0001-6591-8013
Abdalla E A HassanApplied Nucleic Acids Research Center & Chemistry, Faculty of Science, Zagazig 44519, Egypt.
Mohamed S AttiaDepartment of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0003-1964-3420
Zagazig University · EGChitkara University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes (EXOs) were given attention as an extracellular vesicle (EV) with a pivotal pathophysiological role in the development of certain neurodegenerative disorders (NDD), such as Parkinson's and Alzheimer's disease (AD). EXOs have shown the potential to carry pathological and therapeutic cargo; thus, researchers have harnessed EXOs in drug delivery applications. EXOs have shown low immunogenicity as natural drug delivery vehicles, thus ensuring efficient drug delivery without causing significant adverse reactions. Recently, EXOs provided potential drug delivery opportunities in AD and promising future clinical applications with the diagnosis of NDD and were studied for their usefulness in disease detection and prediction prior to the emergence of symptoms. In the future, the microfluidics technique will play an essential role in isolating and detecting EXOs to diagnose AD before the development of advanced symptoms. This review is not reiterative literature but will discuss why EXOs have strong potential in treating AD and how they can be used as a tool to predict and diagnose this disorder.

Indexed as

Alzheimer DiseaseAnimalsExosomesHumanscargodiagnosisdrug deliveryexosomesmicrofluidicsneurodegenerative disorderstreatment

Identifiers

PMID34639135
PMCPMC8509246
OpenAlexW3202186439

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.